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Introduction
Pemphigus is a group of acquired autoimmune blister-
ing diseases of the skin and/or mucous membranes
characterized by autoantibodies against the cell surface
of epidermal keratinocytes.1 There are 2 major sub-
types in our daily practice: pemphigus foliaceus (PF)
and pemphigus vulgaris (PV). The 2 types show distinct
clinical and histopathologic features and are usually
distinguishable from each other. PF patients display
clinically superficial blisters and erosions mainly on the
face and trunk without involvement of the oral mucosa,
and histopathologically show subcorneal acantholytic
bullae. In contrast, PV patients present clinically with
flaccid blisters and persistent erosions preferentially on
the intertriginous regions, almost always associated
with oral mucosal lesion, and histopathologically show
suprabasilar acantholytic bullae in the lower epidermis.
Recent progress in molecular biology has revealed that
the major antigens in PF and PV are the desmosomal
glycoproteins desmoglein 1 (Dsg1) and desmoglein 
3 (Dsg3),2–6 respectively. Both Dsg1 and Dsg3 are
extracellular domains of the desmosomal adhesion mol-
ecules that belong to the cadherin family, are expressed
in stratified squamous epithelia and play pathogenic roles
in blister formation in PF and PV, respectively. Up till
now, the diagnosis of autoimmune blistering diseases
has relied on clinical manifestations, histopathologic
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findings and either direct immunofluorescence (DIF)
or indirect immunofluorescence (IIF). However, the
result of immunofluorescence may be negative in some
cases, and the cell staining pattern of IF test is identical
between PV and PF. Recently, a novel enzyme-linked
immunosorbent assay (ELISA) against Dsg1 and Dsg3
has become commercially available and found to be
extremely sensitive and specific.7–12 Moreover, recent
studies show that ELISA index values fluctuate in par-
allel with disease activity, and provides a valuable tool
to monitor disease activity.7,8,13–15
To date, the usefulness of Dsg1 and Dsg3 ELISAs 
in the diagnosis and monitoring of the disease activity
of pemphigus in the Taiwanese population has never
been reported. Given these considerations, we collected
sera from pemphigus patients, and performed Dsg1
and Dsg3 ELISAs to determine the sensitivity and
specificity of the ELISA test. We also checked if the
ELISA scores correlated with clinical disease activity.
Methods
Human sera
From February 2003 to April 2006, subjects with
clinically blistering diseases were included in our
study. We performed skin biopsies and collected serum
from these subjects before treatment. Histopathologic
examinations including hematoxylin-eosin stain, DIF
(IgG, IgA, IgM, C3 and type IV collagen included)
and IIF were performed. All serum samples were also
tested with Dsg3 and Dsg1 ELISAs. Serial serum sam-
ples from 6 patients with PV and 1 patient with PF
were collected and used for correlation with disease
activity.
Dsg3 and Dsg1 ELISAs
Dsg3 and Dsg1 were measured using ELISA (Medical
and Biological Laboratories Co. Ltd., Nagoya, Japan).
The intraassay and interassay variations were both
< 15% for each sample according to the manufacturer’s
instructions. This assay is generally not interfered with
by factors such as the level of hemoglobin, bilirubin, or
rheumatoid factor, but using highly hemolysed samples
or highly lipemic samples should be avoided.
Statistical analysis
All statistical data are presented as mean± standard error
of the mean (SEM). We used the generalized linear
model repeated measurement method to determine
the correlation between the ELISA scores and disease
activity. Comparison between groups was calculated
using Student’s t test.
Results
Characteristics of patients with pemphigus
Sera were obtained from 143 patients with clinically
blistering disease, including PF (n=9), PV (n=20), bul-
lous pemphigoid (BP) (n=72), dermatitis herpetiformis
(DH) (n=1) and non-autoimmune mediated blistering
diseases (n=41). Diagnoses were confirmed via histopa-
thologic and immunofluorescence tests, and all patients
from both PV and PF groups showed positive DIF with
IgG or C3 staining of keratinocyte cell surface. The
average ages of PV patients and PF patients were 56 ±
3.38 years (range, 26–77 years) and 68.3±6.94 years
(range, 29–91 years), respectively (Table 1). The male:
female ratios in PV and PF patients were 7:3 (14 males,
6 females) and 2:1 (6 males, 3 females), respectively.
Dsg1 and Dsg3 ELISA analysis from 
pemphigus patients and controls
For Dsg1 ELISA, 9 of 9 sera from PF patients (100%)
and 19 sera from 20 PV patients (95%) exceeded the
cut-off value, while 3 of 72 sera from BP patients
(4.2%), none from the DH patient, and none of 41 sera
from patients with non-autoimmune bullous diseases
(0%) exceeded the cut-off value (Table 2). For Dsg3
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Table 1. Anti-desmoglein (Dsg)1 and anti-Dsg3 value (unit/mL) 
of each pemphigus vulgaris (PV) and pemphigus foliaceus (PF)
patient*
PV PF
Dsg3 Dsg1 Dsg3 Dsg1
PV 1 150.7 44.4 PF 1 0 184.0
PV 2 76.3 141.27 PF 2 3.7 52.3
PV 3 235.3 216.6 PF 3 0.8 185.0
PV 4 126.81 223.75 PF 4 9.9 226.4
PV 5 193.48 255.0 PF 5 0.7 173.2
PV 6 193.23 245.09 PF 6 0 193.8
PV 7 198.7 164.4 PF 7 0.6 191.9
PV 8 158.2 67.1 PF 8 1.0 200.2
PV 9 163.9 106.7 PF 9 1.1 131.1
PV 10 150.8 98.0
PV 11 158.0 164.0
PV 12 203.6 174.7
PV 13 151.7 113.6
PV 14 67.3 72.6
PV 15 27.9 99.6
PV 16 27.7 109.2
PV 17 37.6 30.7
PV 18 15.5 90.6
PV 19 0.6 4.6
PV 20 0.1 176.6
*Cut-off positive index value of anti-Dsg1 and anti-Dsg3 was 20 unit/mL.
ELISA, 17 of 20 sera from PV patients (85%) showed
positive scores above the cut-off value, compared with
none of 9 sera from PF patients (0%), 1 of 72 sera from
BP patients (1.4%), none from the DH patient, and
none of 41 sera from patients with non-autoimmune
bullous diseases (0%). Thus, the sensitivities of Dsg3 in
PV and Dsg1 in PF were 85% and 100%, respectively.
The specificities of Dsg3 in diagnosing PV and Dsg1
in PF were 99.1% and 97.4%, respectively. Additionally,
the positive predictive value, negative predictive value,
positive likelihood ratio and negative likelihood ratio
in diagnosing PV were 0.94, 0.97, 96.9 and 0.151,
respectively. The positive predictive value, negative
predictive value, positive likelihood ratio and negative
likelihood ratio in diagnosing PF were 0.75, 1.00, 38
and 0, respectively.
Among the 17 Dsg3 ELISA-positive PV patients, 11
patients had both oral mucosal and cutaneous involve-
ment (named group 1), while 5 patients had only skin
lesions (named group 2), and 1 had only oral mucosal
involvement (named group 3). The average Dsg3 and
Dsg1 values of group 1 patients were 164.13 ± 12.6
and 156.94 ± 21.8, respectively. The average Dsg3 and
Dsg1 values of group 2 patients were 95.64 ± 35.2
and 113.94 ± 16.8, respectively. The Dsg3 and Dsg1
values of the group 3 patient were 37.6 and 30.7,
respectively. The difference in Dsg1 ELISA titers
between group 1 and group 2 patients was not signif-
icant (p = 0.142). The difference in Dsg3 ELISA titers
between group 1 and group 3 patients was also not
significant (p = 0.126).
ELISA scores to monitor disease activity
We used the dosage of systemic steroid as the indica-
tor of disease activity. When the dosage was tapered, it
meant clinical improvement of the disease. If the disease
flared up, the dosage was increased. The correlation
between ELISA titers and prednisolone dosage in each
patient was plotted according to the time course. The
concomitantly used steroid-sparing agents were also
plotted (Figures 1 and 2A). In PV patients 3, 4 and 
5, the Dsg3 ELISA titers decreased in parallel with
disease activity and increased when the patient had a
flare-up. In PF patients, the Dsg1 ELISA titers fluc-
tuated in parallel with disease activity over the time
course. The correlation of average prednisolone dos-
age and average ELISA titers of 6 PV patients at each
sampling time is also shown in Figure 2B. At the 
second to fourth samplings, ELISA Dsg3 titers fluc-
tuated in parallel with prednisolone dosage. When
generalized linear model repeated measurement meth-
od was used to determine the correlation between
disease activity and ELISA Dsg3 titers, the difference
in Dsg3 titers in the within-subjects analysis was of
borderline significance (p = 0.057), and the between-
subjects analysis of Dsg3 titers showed a significant
difference (p = 0.016).
Discussion
We evaluated the Dsg1 and Dsg3 ELISA tests with a
large number of serum samples obtained from patients
with pemphigus, BP and patients with other blistering
diseases. The male:female ratios in PV and PF patients
were 7:3 and 2:1, respectively. This male predomi-
nance is not consistent with previous reports of equal
sex distribution.16–19 However, because our hospital
serves mainly veterans, the sex difference might not be
meaningful.
In the present study, the sensitivity and specificity
of desmoglein ELISAs were high and were consistent
with previously reported data.7–12 A positive Dsg3
result was indicative of PV, regardless of the associated
Dsg1 result. A negative Dsg3 and a positive Dsg1
indicated a diagnosis of PF. Therefore, PV and PF
could be distinguished by using a combination of Dsg1
and Dsg3 ELISA data.
We used these ELISAs to measure antibody levels of
Dsg1 and Dsg3 and examined their correlation with the
progression of disease activity in 7 pemphigus patients
(6 PV, 1 PF). However, the within-subjects difference
in ELISA Dsg3 titers in each PV patient showed bor-
derline significance (p = 0.057). Therefore, we could
not determine whether desmoglein ELISAs would be
a valuable tool for monitoring disease activity because
of the small sample size in our study.
According to the Dsg compensation hypothe-
sis,20,21 the clinical phenotype of pemphigus is deter-
mined by the underlying Dsg antibody profile22–24
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Table 2. Demographic data of pemphigus vulgaris (PV) and 
pemphigus foliaceus (PF) patients
PV (n = 20) PF (n = 9)
Age, yr* 56 ± 3.38 68.3 ± 6.94
Male/female, n 14/6 6/3
Dsg3 Dsg1
Sensitivity (%) 85.0 100.0
Specificity (%) 99.1 97.4
Positive predictive value 0.94 0.75
Negative predictive value 0.97 1.00
Positive likelihood ratio 96.9 38.0
Negative likelihood ratio 0.151 0
*Mean ± standard error of the mean.
and by the tissue distribution of Dsg1 and Dsg3.
Mucosal PV is seen only in patients with Dsg3 anti-
bodies but no Dsg1 antibodies; PF is seen only in
cases with Dsg1 antibodies but no Dsg3 antibodies.
Mucocutaneous PV may occur in cases with Dsg3
antibodies alone, but severe cutaneous involvement 
is seen only if Dsg1 antibodies are also present. Harman
et al have reported that the severities of cutaneous 
and oral pemphigus are related quantitatively to Dsg1
and Dsg3 antibodies, respectively.25 In our study, both
the difference in Dsg1 ELISA titers between group 1
and group 2 patients and the difference in Dsg3
ELISA titers between group 1 and group 3 patients
were not significant. Thus, our results did not support
the previous report that the higher the Dsg ELISA
titers, the more extensive the lesions. In addition, the
patient who had only oral lesions had both positivity
of Dsg1 and Dsg3. This was also not consistent with the
previous report that mucosal PV is seen only in patients
with Dsg3 antibodies but no Dsg1 antibodies.
J Chin Med Assoc • February 2007 • Vol 70 • No 268
C.H. Huang, et al
0
5
10
15
20
25
30
35
A
C D
F
PV patient 1
PV patient 3
Jul-04 Aug-04
45
35
0
10
20
30
40
50
B PV patient 2
215
D
sg3
 value (unit/m
L)
D
sg3
 value (unit/m
L)
D
sg3
 value (unit/m
L)
D
sg3
 value (unit/m
L)
D
sg3
 value (unit/m
L)
210
205
200
195
190
185
180
211.52
193.48
Aug-04 Sep-04 Oct-04
PV patient 5
Pr
ed
ni
so
lo
ne
 d
os
ag
e 
(m
g/
d)
Pr
ed
ni
so
lo
ne
 d
os
ag
e 
(m
g/
d)
E
0
30
20
54
56
58
60
62
64
66
68
PV patient 6
58.9
61.7
67.3
Sep-04 Dec-04 Feb-06
60
120
60
126.81
28.57
0
20
40
60
80
100
120
140
0
20
40
60
80
100
120
140
Cellcept 2 g/d
Cyclosporin 300mg/d
Cyclosporin 200mg/d
Pr
ed
ni
so
lo
ne
 d
os
ag
e 
(m
g/
d)
Pr
ed
ni
so
lo
ne
 d
os
ag
e 
(m
g/
d)
Pr
ed
ni
so
lo
ne
 d
os
ag
e 
(m
g/
d)
Pr
ed
ni
so
lo
ne
 d
os
ag
e 
(m
g/
d)
210
Jul-04 Aug-04 Sep-04
Time course
105.63
60 60
0
10
20
30
40
50
60
70
0
50
250
200
150
100
42.5
130
164
193.23
PV patient 4
Sep-04 Oct-04 Dec-04 Feb-06 Apr-06
52
53
54
55
56
57
58
59
60
61 60
55
198.7
169.2
150
160
170
180
190
200
Dec-04Sep-04
D
sg3
 value (unit/m
L)
Time course
Time course
0
10
20
30
40
50
60
70
30
15
30
60
0
20
40
60
80
160
140
120
100
16.7
12.5
6.3
85.581.5
151.7
Imuran 50mg/d
Time course
Prednisolone dosage Dsg3 value
Time course Time course
Imuran 100mg/d
Cyclosporin 300mg/d
Figure 1. Correlation between desmoglein (Dsg)3 ELISA titers and prednisolone dosage of each pemphigus vulgaris (PV) patient (A–F) over
a time course. The concomitantly used steroid-sparing agents are shown in boxes for each patient along the time course.
In future, the investigation of immunobullous 
disorders is likely to move towards antigen-specific
techniques. The present study showed that Dsg1 and
Dsg3 ELISAs could provide sensitive, specific, and
reproducible data and allow correct diagnosis of PF
and PV. However, more cases should be studied to
determine whether Dsg1 and Dsg3 ELISAs are useful
in monitoring the disease activity of pemphigus.
In conclusion, our results indicate that desmoglein
ELISAs may serve as adjunct diagnostic tools for the
initial diagnosis of pemphigus.
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